Antibodies
30 August 2024
Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis29 August 2024
Biocon Biologics Secures Market Entry for Bmab 1200, a Proposed Biosimilar to Stelara®, in Europe, UK, Canada, and Japan28 August 2024
Cantargia reports timelines for nadunolimab clinical trials in leukemia and triple negative breast cancer27 August 2024
Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH27 August 2024
Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology22 August 2024
Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer22 August 2024
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers21 August 2024
Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) Second NDA Accepted by NPMA, locally advanced or metastatic EGFR-mutant NSCLC20 August 2024
Lift of Partial Clinical Hold for BNT326/YL202News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports